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Are high flow arteriovenous accesses associated with worse 
haemodialysis?
Acessos arteriovenosos de alto débito estão associados a pior 
hemodiálise?
Introdução: Um débito de sangue de acesso 
arteriovenoso (AV) (Qa) de 400 mL/min é 
geralmente suficiente para uma hemodiálise 
(HD) eficaz, mas alguns acessos continuam 
se desenvolvendo e se tornam acessos de 
alto débito (AAD). Alguns autores postu-
laram que um AAD poderia desviar uma 
porção significativa do sangue dialisado do 
débito cardíaco, o que poderia diminuir a 
eficiência da HD e levar à sobrecarga de 
volume. Objetivo: O objetivo do nosso es-
tudo foi avaliar se o AAD está associado à 
redução da eficiência da HD e/ou à sobre-
carga de volume em pacientes prevalentes 
em HD. Métodos: Foi realizado um estudo 
retrospectivo de 1 ano, e avaliada a eficiên-
cia da HD pela porcentagem de sessões em 
que o Kt/V > 1,4 e a sobrecarga de volume 
avaliada pela bioimpedância. Resultados: 
O estudo incluiu 304 pacientes prevalentes 
em HD, com média de idade de 67,5 anos; 
62,5% eram do sexo masculino; 36,2% 
eram diabéticos, com uma mediana de 
tempo em HD de 48 meses. Dezesseis por 
cento dos pacientes apresentavam AAD 
(definida como Qa > 2 L/min). Na análise 
multivariada, os pacientes com AAD apre-
sentaram maior risco de sobrecarga de 
volume (OR = 2,67; IC95% = 1,06-6,71) 
e sobrecarga severa de volume (OR = 4,06; 
IC95% = 1,01-16,39) e atingiram o peso 
seco com menor frequência (OR = 0,37, 
IC 95% = 0,14-0,94). No entanto, o AAD 
não foi associado uma menor razão Kt/V. 
Conclusão: Nossos resultados sugerem que 
pacientes com AAD apresentam maior ris-
co de sobrecarga de volume. No entanto, 
ao contrário do que foi postulado, o AAD 
não foi associado à diálise menos eficiente, 
medida pelo Kt/V. Ensaios clínicos ran-
domizados são necessários para esclarecer 
essas questões.
Resumo
Palavras-chave: Fístula Arteriovenosa; Débi-
to de Sangue do Acesso; Eficiência.
Introduction: An arteriovenous (AV) 
access flow (Qa) of 400 mL/min is 
usually sufficient for an effective 
hemodialysis (HD), but some accesses 
continue developing and become high 
flow accesses (HFA). Some authors 
postulated that an HFA might shift a 
significant portion of dialyzed blood 
from the cardiac output, which could 
decrease HD efficiency and lead to 
volume overload. Objective: The aim 
of our study was to evaluate if HFA is 
associated with reduced HD efficiency 
and/or volume overload in prevalent 
HD patients. Methods: We performed a 
1-year retrospective study and assessed 
HD efficiency by the percentage of 
sessions in which the Kt/V > 1.4 and 
volume overload by bioimpedance 
spectroscopy. Results: The study 
included 304 prevalent HD patients 
with a mean age of 67.5 years; 62.5% 
were males, 36.2% were diabetics, with 
a median HD vintage of 48 months. 
Sixteen percent of the patients had 
a HFA (defined as Qa > 2 L/min). In 
multivariate analysis, patients with 
HFA presented higher risk of volume 
overload (OR = 2.67, 95%CI = 1.06-
6.71) and severe volume overload (OR 
= 4.06, 95%CI = 1.01-16.39) and 
attained dry weight less frequently 
(OR = 0.37, 95%CI = 0.14-0.94). 
However, HFA was not associated 
with lower Kt/V. Conclusion: Our 
results suggest that patients with HFA 
have higher risk of volume overload. 
However, contrarily to what has been 
postulated, HFA was not associated 
with less efficient dialysis, measured by 
Kt/V. Randomized controlled trials are 
needed to clarify these questions.
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IntRoductIon
Adequate hemodialysis (HD) requires a functional 
vascular access that is able to deliver a flow rate of 
at least 350-400 mL/min with minimal recirculation 
for the total duration of treatment.1,2 The monitoring 
of the access flow (Qa) is very important for the early 
detection of access dysfunction3 such as high flow ac-
cess (HFA). Although a higher blood flow allows easy 
needling and excellent blood flow rate to the dialyzer 
(Qb), it has been related to some systemic deleterious 
consequences.4
There is no exact definition of the Qa level above 
which a HFA should be considered and no consensual 
guideline about the ideal or normal access blood flow. 
The guidelines from the Vascular Access Society de-
fined an arteriovenous fistula (AVF) as a high flow fis-
tula with a Qa between 1-1.5 L/min and a measured 
cardiopulmonary recirculation (CPR) [Qa/cardiac 
output (CO)] greater than 20%.5 In the absence of an 
exact description of a HFA, a Qa > 2 L/min is prag-
matically used as a cut-off point, since it increases the 
risk of cardiac failure in HD patients with a Qa/CO 
> 20-30%.6-8
Considering the structural and functional cardiac 
adaptations associated with an AV access construc-
tion, and especially the higher risk for heart failure 
in patients with HFA, some patients become pre-load 
dependent, which causes intra-dialytic hypotension 
with lower ultrafiltration.6,7 Furthermore, the con-
struction of an AV access leads to the creation of a 
left to right extracardiac shunt, which causes CPR, 
i.e., dialyzed blood from the AV access is directed to 
the right ventricle and pulmonary circulation, is then 
pumped into the systemic circulation and a portion 
of this dialyzed blood re-enters the access. The re-
entrance of the dialyzed and systemic blood mix into 
the access could lead to poor solute clearance.1,7,9 This 
mix decreases the solute concentration between blood 
and dialysate, which reduces the solute removal from 
the blood. Schneditz et al. were the first to show the 
association between CPR and HD efficiency with a 
theoretical model.9,10
Maintaining a HFA could cause functional and 
structural cardiac changes (cardiac toxicity) which 
could in the end reduce the CO. Considering the 
heart has a limited capacity to increase the CO, ac-
cesses with a higher flow deviate a higher proportion 
of the CO, i.e. they have a greater CPR. That way, 
if the same access (with the same Qa - numerator) is 
maintained and the CO is reduced (as a consequence 
of the cardiac toxicity of these accesses - denomina-
tor), it means that the ratio Qa/CO (percentage of 
blood deviated from the CO to the access) is high, 
which means a higher CPR.9-11
Considering these unresolved questions, we per-
formed a study to evaluate if a higher Qa was as-
sociated with reduced HD efficiency and/or volume 
overload in prevalent HD patients. We hypothesized 
that patients with HFA have a lower tolerability to 
ultrafiltration, have more volume overload, and could 
present a high CPR, reducing HD efficiency.
subjects And methods
Study deSign
This was an observational, 1-year retrospective, sin-
gle-center study of a cohort of adult prevalent HD 
patients. The studied population was divided in two 
groups (HFA and non-HFA) according to the mean 
value of the last three Qa measurements, separated by 
at least one month. We defined a HFA as a Qa higher 
than 2 L/min.
All patients were dialyzed with high flux he-
lixone filters (Fresenius®), ultrapure water dialy-
sate (evaluated monthly by kinetic chromogenic 
test) and online post-dilution hemodiafiltration. 
We used the dialysis FX CorDiax600 (Fresenius 
Medical Care), which has an effective surface of 
1.6 m2 and Intrinsic Clearance for Urea (KoA) of 
1.148. All patients included in the study were pre-
scribed 4-hour HD sessions. The median HD vin-
tage was 48 months (IQ range 24-96).
CliniCal CharaCteristiCs
Patient’s data on age, gender, baseline comorbidity 
(diabetes, hypertension, coronary artery disease, peri-
pheral vascular disease, and cerebrovascular disease), 
access type, location, and date of angiographic and 
surgical interventions were all extracted from the cli-
nical database Euclid®.
Biochemical parameters such as hemoglobin and 
albumin (reference value > 4.0 g/dL) were evaluated 
monthly and mean values were determined. Each pa-
tient underwent an echocardiographic examination 
during the study period (M mode and 2-D) and left 
ventricular mass index (LVMI) was calculated by the 
Devereux formula.12
Patients with NYHA class greater than II were ex-
cluded from the study.
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aCCess blood flow (qa) measurement
Access flow was routinely measured by thermo-
dilution, using the Fresenius Medical Care Blood 
Temperature Monitor (BTM) at a Qb of 300 mL/min 
using a twister device. This measurement is always 
started in the first hour of treatment. In grafts, the Qa 
was assessed monthly and in fistulas it was assessed 
depending on the measurement itself: if the last mea-
sure was lower than 600 mL/min, the Qa was mea-
sured monthly, if it was between 600 and 1000 mL/
min, the evaluation was postponed to 4 months, and 
if the last Qa was higher than 1000 mL/min, the next 
evaluation was postponed to 1 year.
Volume status assessment
Patient’s volume status was evaluated monthly by bio-
impedance spectroscopy using the Fresenius Medical 
Care Body Composition Monitor (BCM).13 Both the 
absolute and relative fluid overload were assessed. 
According to BCM validation studies, the volume sta-
tus was classified in three categories:
- Dry weight (absolute fluid overload below 1 L)
- Volume overloaded (absolute fluid overload 
above 1.1 L)
- Severe volume overloaded (absolute fluid over-
load above 2.5 L)
deliVered dialysis dose
Kt/V was measured using the Fresenius Medical Care 
Online Clearance Monitor (OCM) in all HD sessions 
during 1 year (approximately 139 sessions per patient). 
For each patient, we calculated the percentage of sessions 
in which the Kt/V goal (Kt/V > 1.4) was achieved.
StatiStical analySiS
Variables were reported as frequencies for categorical 
variables, mean values with SD for continuous varia-
bles with normal distribution, and median values wi-
th interquartile ranges for continuous variables non-
-normally distributed. We applied Shapiro-Wilk test 
to evaluate the normality of our data. Comparison 
between groups (HFA and non-HFA) was perfor-
med using T-Test for normally distributed variables, 
Wilcoxon test for non-normally distributed variables 
and x2 test for categorical variables.
For the purpose of the analysis, HFA was used as 
predictor and volume overload, mean value of Kt/V 
throughout the year, and % of Kt/V > 1.4 as outcome 
variables.
The relationship between HFA and volume over-
load was studied using univariate and multivariate 
logistic regression models to adjust for potential con-
founders. The multivariable analysis was adjusted for 
age (statistically different in the univariable analysis), 
HD vintage, serum albumin, and LVMI.
The relationship between HFA and Kt/V was stud-
ied using the Spearman correlation in a univariate 
analysis. Multivariate analysis was performed using a 
linear regression model. These models were adjusted 
for age (statistically different in the univariate analy-
sis) and for dry weight, pump speed, and time of HD 
per session (important determinants of HD efficacy).
Statistical analysis was performed with SPSS sys-
tem 21.0. For all comparisons, a p < 0.05 was consid-
ered statistically significant.
Results
POPulatiOn
The study included 304 patients, 190 (62.5%) males, 
with a mean age of 67.5 ± 14.8 years old. A total 
of 110 (36.2%) patients were diabetic, 219 (72.0%) 
had hypertension, 90 (29.6%) had coronary artery 
disease, 70 (23%) peripheral arterial disease and 63 
(20.7%) had cerebrovascular disease (Table 1).
Variable Patients (n = 304)
Age, years 67.5 ± 14.8
Gender, male 190 (62.5)
Race, Caucasian 288 (94.7)
HD vintage, months 48 (24-96)
HD session duration, minutes 245 (245-247)
Blood pump speed (Qb), mL/min 442.7 ± 17.9 
Diabetes 110 (36.2)
Hypertension 219 (72.0)
Access type
Fistula 225 (74.0)
Graft 79 (26.0)
Access location, proximal 193 (63.5)
Access with Qa ≥ 2 L/min 48 (15.8)
Mean Kt/V 1.98 ± 0.39
Dry weight (OH < 1 L) 269 (88.5)
Volume overload (OH > 1 L) 35 (11.5)
Severe volume overload (OH > 2.5 L) 10 (3.3)
tAble 1 clinical, vaScular acceSS, and   
 hemOdialySiS ParameterS Of the Studied  
 POPulatiOn
* Values reported as mean±SD, median (interquartile range) or 
frequencies [n (%)].
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All patients had a functioning AV access for HD: 
approximately three quarters (n = 225; 74.0%) had 
a fistula and one quarter (n = 79, 26%) had a graft. 
In our population, 15.8% of the patients had a HFA, 
i.e. an access with Qa > 2 L/min. The mean Kt/V value 
was 1.98 and 88.5% of the patients achieved their dry 
weight.
Patients with a HFA were younger (62.1 vs. 68.5 
years, p = 0.015), were under HD for longer time (60 
vs. 48 months, p = 0.034) and had a lower prevalence 
of diabetes (14.6 vs. 40.2%, p < 0.001). There was 
no significant difference in gender distribution and 
prevalence of coronary artery disease, cerebrovas-
cular disease, and peripheral artery disease between 
groups (Table 2).
In respect to access characteristics, we found that 
Qa ≥ 2 L/min was more frequent in fistulas com-
paratively to grafts (91.7 vs. 8.3%, p = 0.001) and 
in proximal accesses than in distal (75 vs. 25%, p = 
0.043).
Qa < 2 L/min (n = 256) Qa ≥ 2 L/min (n = 48) p
Age, years 68.5 ± 14.1 62.1 ± 17.5 0.015
Gender, male 155 (60.5) 35 (72.9) ns
Race, Caucasian 245 (95.7) 43 (89.6) ns
HD vintage, months 48 (24-84) 60 (27-108) 0.034
HD sessions duration, minutes 245 (245-247) 246 (245-247) ns
Blood pump speed (Qb), mL/min 442.7 ± 18.0 443.3 ± 17.8 ns
Dry weight (kg) 69.9 ± 13.5 70.7 ± 11.3 ns
Diabetes 103 (40.2) 7 (14.6) < 0.001
Hemoglobin (g/dL) 11.1 ± 1.1 11.2 ± 1.1 ns
Serum Albumin (g/dL) 4.0 ± 0.3 4.1 ± 0.3 ns
Access type
0.001Fistula 181 (70.7) 44 (91.7)
Graft 75 (29.3) 4 (8.3)
Access location, proximal 157 (61.3) 36 (75.0) 0.043
Pulse pressure, mmHg 78.0 ± 15.9 71.7 ± 17.6 0.037
Mean Blood Pressure, mmHg 92.0 ± 13.2 90.0 ± 14.5 ns
Heart Rate, bpm 71.7 ± 10.6 72.1 ± 10.0 ns
Left Ventricular Mass Index (g/m2) 130.2 ± 30.9 146.2 ± 47.3 0.035
Left Ventricular Ejection Fraction (%) 60.7 ± 13.6 55.1 ± 17.8 ns
Pulmonary Artery Pressure (mmHg) 39.2 ± 12.9 34.1 ± 13.3 ns
Hypertension 182 (71.1) 37 (77.1) ns
Coronary Artery Disease 80 (31.3) 10 (20.8) ns
Peripheral artery disease 63 (24.6) 7 (14.6) ns
Cerebrovascular disease 56 (21.9) 7 (14.6) ns
tAble 2 clinical and labOratOry characteriSticS Of PatientS with hfa and nOn-hfa
* Values reported as mean ± SD, median (interquartile range) or frequencies [n (%)].
Patients with a HFA had higher left ventricular 
mass index (146.2 vs. 130.2 g/m2, p = 0.035) and low-
er pulse pressure (71.7 vs. 78.0 mmHg, p = 0.037). 
Although not statistically significant, patients with a 
HFA presented a higher proportion of hypertension 
(77.1 vs. 71.1%) and lower LVEF (55.1 vs. 60.7%).
• Volume overload
Eighty-nine percent of the patients achieved the 
dry weight and 11.5% had volume overloaded (OH 
> 1 L).
In univariate analysis, we found that patients with 
a HFA had severe volume overloaded more frequent-
ly (2.3 vs. 8.3 %, OR 3.79, 95%CI = 1.03-13.97). 
However, the distribution of patients for dry weight 
and volume overload categories was not different be-
tween groups.
A logistic regression analysis was performed to 
verify the effect of having a HFA on the chance of 
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having volume overload adjusting for age (years), HD 
vintage (months), serum albumin (g/dL), and LVMI 
(g/m2). We found that an access with Qa > 2 L/min 
was significantly associated with the risk of volume 
overload (OR = 2.67, 95%CI = 1.06-6.71) and severe 
volume overload (OR = 4.06, 95%CI = 1.01-16.39). 
In the same analysis we also found that patients with 
HFA attained the dry weight less frequently (OR = 
0.37, 95%CI = 0.14-0.94).
• Kt/V
The mean Kt/V of our population was 1.98 and 
the Kt/V goal was attained in 97% of the sessions. 
Patients with a HFA did not have a different mean 
Kt/V value or a different proportion of sessions in 
which the Kt/V was attained comparing with patients 
with an AV access of Qa ≤ 2 L/min.
We performed a multiple regression analysis to in-
vestigate whether the Kt/V value could be predicted 
based on Qa > 2 L/min, in a model adjusted to age 
(years), dry weight (Kg), blood pump speed (mL/min) 
and time of each HD session (minutes). This model 
was not significant (Table 3).
Univariate analysis
Multivariate 
analysis §
Qa < 2 L/min 
(n = 256)
Qa ≥ 2 L/min 
(n = 48)
OR (95% CI) p OR (95% CI)
Dry weight (OH ≤ 1 L) 230 (89.8) 39 (81.3)
0.49 
(0.21-1.12)
ns
0.37 
(0.14-0.94)
volume overload (OH > 1 L) 26 (10.2) 9 (18.8)
2.04 
(0.89-4.68)
ns
2.67 
(1.06-6.71)
Severe volume overload (OH > 
2.5 L)
6 (2.3) 4 (8.3)
3.79 
(1.03-13.97)
0.056
4.06 
(1.01-16.39)
% VO > 15% 52 (22.0) 9 (21.4)
0.965 
(0.43-2.15)
ns
0.79 
(0.33-1.93)
% VO > 20% 12 (5.1) 3 (7.1)
1.44 
(0.39-5.32)
ns
1.65 
(0.39-6.99)
Kt/V 1.99 ± 0.40 1.93 ± 0.35
0.52 
(0.07-1.18)
ns
0.03 
(0.00-3.09)
% of sessions that Kt/V was 
attained in 1 year
97.2 95.3
1.69 
(0.34-8.40)
ns
1.33 
(0.20-8.71)
* Values expressed as mean±SD, median or frequencies [n (%)]. Relative pre-dialytic volume overload (% VO) was calculated as: % VO = VO [L]/ 
extracellular water [L]*100 at baseline.
§ Multivariate analysis: logistic regression for binary outcomes and linear regression for continuous outcomes. The models were adjusted for age 
(years), dry weight (kg), pump speed (mL/min), and HD sessions length (minutes) to study the HD efficiency (Kt/V) and for age, HD vintage, serum 
albumin (g/dL) and LVMI to study the volume status.
tAble 3 efficiency and vOlume StatuS characteriSticS Of PatientS with hfa and nOn-hfa (univariate and   
 multivariate analySiS)
We also compared the patients with Qa < 1 L/min 
with patients with Qa > 1 L/min and the results were 
not different from those described above.
dIscussIon
We believe this is the first study that investigated the 
relationship between HFA, volume overload, and HD 
efficiency. We found that having a HFA, at least when 
the Qa was greater than 2 L/min, was associated with 
a higher risk of volume overload, but not to dialysis 
efficiency, evaluated by Kt/V.
There are many studies about the immediate and 
late cardiac and neurohormonal adaptations after the 
creation of an AV access. These modifications lead 
to a compensatory increase in CO, heart rate, car-
diac contractility, and blood volume.10,14 Some studies 
about the cardiac hemodynamic effects of AV accesses 
suggest that patients with a HFA have elevated CO, 
higher cardiac index, less subendocardial perfusion, 
and increased left ventricular cavity size.5,14-16 These 
patients could also present more cardiac diastolic dys-
function and higher ANP/BNP levels.10
Several cases of high-output cardiac failure in pa-
tients with a HFA have been reported,17-19 especially 
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in transplanted patients. A Qa/CO ratio higher than 
0.3 is considered a risk factor for high-output cardiac 
failure, however this cut-off has not yet been validat-
ed in prospective trials.20 Other studies showed echo-
cardiographic and clinical improvement following AV 
access closure or flow reduction.21-25 An established 
relationship between Qa and CO was described by 
Basile et.al.6 in a 3rd order polynominal regression 
model, in which the CO did not vary significantly for 
Qa between 0.95 and 2.2 L/min. These authors also 
show that a Qa > 2 L/min was a strong predictor of 
high-output heart failure.6
Prospective studies found indirect signs (e.g. in-
creased serum ANP) that the creation of an AV access 
develops a state of volume overload, at least immedi-
ately after the creation,10,26 which have been demon-
strated in traumatic fistulas. Besides the increase in 
blood volume, it was also demonstrated that in trau-
matic fistulas the greater the fistula blood flow the 
greater the increase in blood volume.27
In our cohort study, patients with a HFA present-
ed higher LVMI, and although not statistically signifi-
cant, these patients also had a higher proportion of 
hypertension and lower LVEF.
The cardiac adaptations in patients with a HFA 
could be associated with a lower tolerability to ultra-
filtration and interfere with the achievement of dry 
weight, which could have prognostic consequences.7 
In this study, we hypothesized that a higher Qa is as-
sociated with a higher risk of volume overload and 
our findings support this hypothesis. The odds ratio 
of volume overload and severe volume overload were 
2.67 and 4.06 times higher for patients with a HFA 
than for patients with Qa < 2L/min. We also found 
that the patients with a HFA attained dry weight less 
frequently, with an odds ratio 0.37 times lower com-
pared to patients with Qa < 2 L/min.
The making of an AV access leads to a left to right 
extra-cardiac shunt causing CPR, and a significant 
proportion of dialyzed blood re-enters the access, 
which could theoretically lead to poor solute clear-
ance. Thus, accesses with higher blood flow drive a 
higher percentage of CO to the access, i.e., have great-
er CPR. Some authors postulated that a persistent 
HFA could be associated with under-dialysis.8 These 
authors reinforce the important potential for cardiac 
toxicity, but also the potential systemic consequences 
of a HFA, such as the “global steal syndrome”, un-
der-dialysis, and wasting.7,27
Contrarily to what has been postulated, the higher 
CPR related with a HFA is not associated with lower 
HD efficiency. We should note that HD adequacy has 
multiple components, such as nutrition, anemia man-
agement, and mineral and bone disorders. Therefore, 
this issue needs to be clarified in prospective random-
ized studies, where other components of HD efficien-
cy are considered, besides the Kt/V.
Although a previous study did not find an increased 
risk of all-cause mortality associated with higher Qa,28 
studies are needed to investigate if, when, and which pa-
tients would benefit from the reduction of Qa in HFA.29
Our results corroborate the new “patient first” para-
digm currently accepted in the field of vascular accesses 
for hemodialysis in opposition to the old “fistula first” 
paradigm. This change was based on data suggest-
ing that the presence of an AVF can contribute to the 
high CV morbidity in HD patients, called by Richard 
Amerling “arteriovenous fistula toxicity”.7 With this new 
paradigm, experts want to alert that AVF is not the best 
choice for all patients. The best vascular access for each 
patient must be defined individually, based on the risk of 
heart failure and/or ischemic steal syndrome, CV comor-
bidities, patient desires, life expectancy, etc.7,8
A limitation of our study is its retrospective nature 
and an HD population from a single center, which 
could interfere in the generalization of our results. 
Another important limitation is that CO, which is a 
very important determinant of Qa, was not evaluated 
in our study, as echocardiography routine performed 
in our center does not include doppler study.
In conclusion, our results suggest that a HFA is asso-
ciated with higher risk of volume overload and lower ca-
pacity of reach dry weight. Contrarily to what has been 
postulated, patients with a HFA do not have less efficient 
HD, measured by Kt/V. Randomized controlled trials are 
needed to examine whether higher Qa adds difficulty in 
reaching dry weight, if it is cardiovascular risk factor, and 
if it is associated with under dialysis.
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